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HI HSCT (%) MR HSCT (%)
Number 29 23
Age (range) 49 (21-65) 49 (27-64)
Sex (M/F) 19/10 17/6
Median CD34 cells (x 106/kg) 4.7 4.32
Disease
AML/MDS 16 (55) 11 (48)
ALL 11 (38) 5 (22)
NHL 2 (7) 7 (30)
Conditioning
MA 29 (100) 21 (91)
RIC 0 2 (9)
Outcomes:
Median ANC recovery -days 11 11
Median Platelet recovery- days 17 18
aGVHD III-IV 3 (10) 1 (4)
cGVHD 5 (12) 1 (4)
CMV Reactivation 10 (35) 4 (17)
Deaths 5 (17) 5 (22)
Cause of Death:
Infection 0 0
Relapse 4 (14) 4 (17)
Toxicity 1 (3) 1 (4)
GVHD 0 0
Figure 3. mRNA-electroporated, CDs from MM patients induce autologous
antigen-speciﬁc CTLs after autologous stem cell transplantation (ASCT).
Cytokine-generated, moDCs derived form peripheral blood were eclectropo-
rated with WT1 mRNA, terminally matured by a combination of inﬂammatory
cytokines, and then added in serial doses to triplicate micorwells containing 1
 102 autologous T cells obtained pre- and post-ASCT (d +11, 30, and 90) and
cultured with IL 15 for 7 days, Antigen-speciﬁc target cell lysis by CTLs stim-
ulated by WT1 mRNA-electroporated moDCs was evaluated using a ﬂow
cytometry-based assay.
Target cells for were 697 cells (HLA-A+0201+, WT1+ cell line). Speciﬁc lysis is
plotted against the y-axis comparing the lysis activity of T cells stimulated by
mRNA-electroporated moDCs at the indicated time points (d +11, 30, and 90)
after ASCT and compared with pre-ASCT value (pre). Data points ate the av-
erages  SEM of triplicate means from one experiment.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S57eS71S62differences in the pattern of immune reconstitution between
groups.
Conclusion: In addition to decreased disease burden, a
favorable shift in Treg to effector T cell ratios characterizes
the early post-transplant period. This provides a critical
window for immunotherapeutic modalities like vaccines and
checkpoint blockade agents to induce antitumor immunity.60
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Haploidentical (HI) HSCT enfranchises patients (pts) who
have no HLA matched donor. In the 2-step approach to HI
HSCT, a large ﬁxed dose of allogeneic T cells are infused after
conditioning, followed 2 days later by cyclophosphamide
(CY) to induce bidirectional tolerance. A CD34 selected stem
cell product is infused after CY. CYeradicates only activated T
cells, supporting post HSCT immune reconstitution (IR) and
low rates of GVHD. Given the favorable results with this
approach in HI HSCT, we applied the regimen to MR HSCT.
Delivering a ﬁxed dose of donor T cells within the same
2 step regimen provides a level baseline from which to
evaluate whether HI HSCT is inherently inferior to MR HSCT.
Thus, we compared IR and clinical outcomes of patients
undergoing HI HSCT versus MR HSCT using this approach.Flow cytometric assessment of T-cell subsets was used to
measure IR at day (D) +28 and +90 in pts undergoing HI and
MR HSCT. Pts were evaluable for IR analysis if they had full
donor chimerism, had no evidence of disease, and were fully
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conditioning regimen was 12 Gy of TBI over 4 days. 2 MR
HSCT pts received a reduced intensity conditioning with
Fludarabine/Cytarabine and 2 Gy of TBI. Conditioning was
immediately followed by an infusion of 2 x 108 CD3+ cells/kg
donor T cells (step 1). CY 60 mg/kg/d x 2 was given starting
2 days after the T cell infusion. Tacrolimus and MMF were
begun on day -1. A CD 34 selected product was infused on
day 0 (step 2).
Both HI and MR showed equivalent early IR in all T-cell
subsets with no statistical differences between them. There
were no deaths from infections or GVHD. GVHD was
controlled in all cases with steroids and/or photopheresis.
Each group had 1mortality from regimen related toxicity. No
rejections or engraftment failures were observed. CMV
reactivation was higher in the HI group, with no CMV organ
disease. After a median follow up of 18 months (range 2-60),
both HI and MR HSCT had similar survival rates, 83% and 78%
respectively.
Using the same 2 step approach, which allows uniform T cell
dosing, comparable outcomes were seen in terms of IR,
signiﬁcant GVHD, incidence of regimen-related mortality
and survival in HI vs MR HSCT recipients, albeit with higher
CMV reactivation. The establishment of this "level playing
ﬁeld" in terms of non-relapse mortality, allows for future
inquiries which compare graft versus tumor effects between
the 2 donor sources with less confounding inﬂuences.LATE EFFECTS/QUALITY OF LIFE/PSYCHOSOCIAL ISSUES
61
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Background: It has been 20 years since the ﬁrst unrelated
cord blood transplant (CBT) and many CBTs that followed,particularly early on, were performed in young children.
Improved donor selection, management of transplant-related
complications, and supportive care have led to increasing
numbers of long-term survivors of CBT. Infants and young
children who undergo allogeneic CBT are at increased risk for
certain late effects due to organ immaturity at the time of
transplantation, particularly if radiation is used. Myeloablative
regimens using Busulfan (Bu) have been employed to elimi-
nate radiation exposure and associated consequences. In this
single center retrospective review, late effects in young
children receiving CBT following myeloablative, Bu-based
conditioning regimens are reported.
Methods: The records of 215 consecutive patients from 1993
to 2008 who received Bu containing conditioning regimens
for allogeneic CBT at< 2 years of age were reviewed. Of these,
105 patients who survived at least 5 years post-CBT were
identiﬁed. A database was created to capture information
regarding patient demographics, diagnosis, cord blood unit
(CBU) characteristics, graft-related outcomes, and incidence
and severity of organ system-speciﬁc late effects.
Results: Of the 182 patients who underwent CBT at least 5
years prior, 58% were alive at 5 years post-CBT (n ¼ 105).
Median time from transplant was 10.8 years (range 5.1e19.9
years). Sixty-four percent of these patients were male and
83% were Caucasian. Diagnoses included inherited metabolic
disease (58%, majority were Krabbe disease and Hurler
syndrome), leukemia (20%), immune deﬁciency (16%), bone
marrow failure/myelodysplastic syndrome (4%), and hemo-
globinopathy (2%). Median age at time of CBT was 1.04 years
(range 0.06-1.96 years). All patients received Bu containing
regimens. Most received Bu/Cyclophosphamide/ATG (71%) or
Bu/Melphalan/ATG (17%). CBUs were human leukocyte an-
tigen (HLA) matched at 4/6 (43%), 5/6 (45%), and 6/6 (12%). Of
the 112 patients who underwent CBT at least 10 years prior,
57 and 54% were alive at 5 and 10 years post-CBT, respec-
tively. There were no deaths after 10 years post-CBT. The
most commonly observed late effects included dental
problems, short stature, and pubertal delay/gonadal failure.
Pulmonary dysfunction was less common, and the majority
of cases were mild. We will describe the characteristics of
this cohort and where possible, compare these with existing
data regarding late effects after allogeneic transplantation
using TBI containing regimens.
Conclusions: This is the ﬁrst report of late effects of Bu-based
conditioning in a large cohort of patients who were very
young at time of CBT. These results will inform clinical care
and guidelines for long-term follow-up, as well as add to the
growing information regarding late effects of HSCT in general.62
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Background: Previous research suggests that chronic graft-
versus-host disease (cGVHD) is a risk factor for depressive
symptomatology among allogeneic hematopoietic cell
transplant (HCT) survivors. The extent to which coping
modiﬁes this risk is unknown, however.
Objective: The goal of the current study was to determine
whether coping strategies modify risk of depression among
patients with cGHVD.
